BR112013004254A2 - conjunto, método, sistema, e aparelho para avaliação do nível de partículas de lipoproteína específicas presentes em um fluido corporal - Google Patents

conjunto, método, sistema, e aparelho para avaliação do nível de partículas de lipoproteína específicas presentes em um fluido corporal

Info

Publication number
BR112013004254A2
BR112013004254A2 BR112013004254A BR112013004254A BR112013004254A2 BR 112013004254 A2 BR112013004254 A2 BR 112013004254A2 BR 112013004254 A BR112013004254 A BR 112013004254A BR 112013004254 A BR112013004254 A BR 112013004254A BR 112013004254 A2 BR112013004254 A2 BR 112013004254A2
Authority
BR
Brazil
Prior art keywords
assessing
level
body fluid
particles present
kit
Prior art date
Application number
BR112013004254A
Other languages
English (en)
Other versions
BR112013004254B1 (pt
Inventor
Debra Linn Hicks
Joseph Paul Mcconnell
Philip Guadagno
Original Assignee
Helena Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/861,829 external-priority patent/US20120052593A1/en
Application filed by Helena Lab filed Critical Helena Lab
Publication of BR112013004254A2 publication Critical patent/BR112013004254A2/pt
Publication of BR112013004254B1 publication Critical patent/BR112013004254B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

conjunto, método, sistema, e aparelho para avaliação do nível de partículas de lipoproteína específicas presentes em um fluido corporal. são revelados um conjunto, um método, um sistema, e um aparelho para a avaliação do nível de particulas de liproproteína e específicas presentes em um fluido corporal. os níveis determinados podem ser usados para predizer o risco para desenvolver várias doenças relacionadas com as partículas de lipoproteína.
BR112013004254-0A 2010-08-24 2011-08-23 método para avaliação do nível de partículas de lipoproteína específicas presentes em um fluido corporal BR112013004254B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/861,829 US20120052593A1 (en) 2010-08-24 2010-08-24 Assay for determination of levels of lipoprotein particle number in bodily fluids
US12/861,829 2010-08-24
US12/877,733 2010-09-08
US12/877,733 US9488666B2 (en) 2010-08-24 2010-09-08 Assay for determination of levels of lipoprotein particles in bodily fluids
PCT/US2011/048733 WO2012027318A1 (en) 2010-08-24 2011-08-23 Assay for determination of levels of lipoprotein particles in bodily fluids

Publications (2)

Publication Number Publication Date
BR112013004254A2 true BR112013004254A2 (pt) 2016-08-02
BR112013004254B1 BR112013004254B1 (pt) 2020-11-03

Family

ID=45003032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004254-0A BR112013004254B1 (pt) 2010-08-24 2011-08-23 método para avaliação do nível de partículas de lipoproteína específicas presentes em um fluido corporal

Country Status (8)

Country Link
US (2) US9488666B2 (pt)
EP (1) EP2609432B1 (pt)
JP (2) JP5981433B2 (pt)
AU (1) AU2011293548B2 (pt)
BR (1) BR112013004254B1 (pt)
CA (1) CA2808821C (pt)
ES (1) ES2632760T3 (pt)
WO (1) WO2012027318A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181267A1 (en) 2012-05-29 2013-12-05 Health Diagnolstic Laboratory. Inc. Compsition and method for gel electrophoresis with in-situ clalibration
WO2013188879A1 (en) * 2012-06-16 2013-12-19 Atherotech, Inc. Measurement of serum lipoproteins
WO2014137828A1 (en) 2013-02-28 2014-09-12 Health Diagnostic Laboratory, Inc. Fluorescent in-situ detection of lipid particle apolipoproteins within primary electrophoretic matrix
US9759682B2 (en) 2013-08-09 2017-09-12 True Health Ip Llc Applicator comb for gel electrophoresis
AU2014364401A1 (en) 2013-12-18 2016-07-07 Helena Laboratories Corporation Lp(a) subform size identification using zonal gel immuno-fixation electrophoresis
JP2015141137A (ja) * 2014-01-29 2015-08-03 国立大学法人大阪大学 小腸由来ｈｄｌの取得方法、小腸由来ｈｄｌの評価方法、小腸由来ｈｄｌ増加作用を有する化合物のスクリーニング方法並びに前記化合物を含む小腸由来ｈｄｌ増加薬及び家族性高コレステロール血症治療薬
CA2965675A1 (en) 2014-10-27 2016-05-06 True Health Ip Llc Lp(a) subform size identification by capillary isotachophoresis electrophoresis with laser-induced-fluorescence
WO2017058781A1 (en) * 2015-09-29 2017-04-06 Polymer Technology Systems, Inc. Systems and methods for point-of-care determination of hdl-c and hdl-p
GB2573477A (en) * 2017-03-02 2019-11-06 Motorola Solutions Inc Method and apparatus for gathering visual data using an augmented-reality application
US20220099625A1 (en) 2019-03-02 2022-03-31 Helena Laboratories Corporation Applicator comb with serrated teeth for gel electrophoresis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5917136A (ja) 1982-07-20 1984-01-28 Olympus Optical Co Ltd 電気泳動用測光装置
FR2533704B1 (fr) 1982-09-27 1986-03-21 Spiral Dosage immunologique dans le serum de l'apolipoproteine b des lipoproteines de basse densite
FR2684998B1 (fr) * 1991-12-11 1994-10-28 Sebia Sa Procede de separation de la lp(a) par electrophorese, gels pour la mise en óoeuvre de ce procede, et application a la determination in vitro du risque atherogene lie a la presence de la lp(a).
US20040053321A1 (en) * 1995-06-30 2004-03-18 Patrea L Pabst Holland And Knight Llp Method for makin antibodies immunoreative with an epitope of an apolipoprotein
IT1311904B1 (it) 1999-04-02 2002-03-20 Univ Pavia Metodo per la identificazion del piu' diffuso gene responsabile dimalattia aterosclerotica.
US7062077B1 (en) * 1999-10-29 2006-06-13 Helena Laboratories Corporation Scanner densitometer and data evaluation method
AU2003259222A1 (en) 2002-07-30 2004-02-16 The Regents Of The University Of California Method of diagnosing alzheimer's disease
JP4729580B2 (ja) * 2004-11-24 2011-07-20 三代 岡崎 リポプロテインの分析方法
US20070072302A1 (en) * 2005-09-29 2007-03-29 Berkeley Heartlab, Inc. Method for quantitatively determining the LDL particle number in a distribution of LDL cholesterol subfractions
JP2007248131A (ja) 2006-03-14 2007-09-27 Yamaguchi Univ セルロースアセテート膜を用いたリポ蛋白質の分離方法
US20120052593A1 (en) * 2010-08-24 2012-03-01 Helena Laboratories Corporation Assay for determination of levels of lipoprotein particle number in bodily fluids

Also Published As

Publication number Publication date
JP2016156827A (ja) 2016-09-01
JP2013539540A (ja) 2013-10-24
CA2808821C (en) 2019-10-15
BR112013004254B1 (pt) 2020-11-03
ES2632760T3 (es) 2017-09-15
JP5981433B2 (ja) 2016-08-31
CA2808821A1 (en) 2012-03-01
US9488666B2 (en) 2016-11-08
WO2012027318A1 (en) 2012-03-01
AU2011293548A1 (en) 2013-03-07
US20170131301A1 (en) 2017-05-11
US20120052594A1 (en) 2012-03-01
AU2011293548B2 (en) 2015-07-30
EP2609432B1 (en) 2017-05-10
EP2609432A1 (en) 2013-07-03
JP6505040B2 (ja) 2019-04-24

Similar Documents

Publication Publication Date Title
BR112013004254A2 (pt) conjunto, método, sistema, e aparelho para avaliação do nível de partículas de lipoproteína específicas presentes em um fluido corporal
PH12016502167A1 (en) Hdl theraphy markers
BRPI0822100A2 (pt) Método e sistema para administrar automaticamente processos no desenvolvimento paralelo de um aplicativo por uma interface de usuário gráfica, sistema de desenvolvimento de aplicativo de computador, e, meio legível por computador de instruções
AR087733A1 (es) Metodos y aparatos para la deteccion no destructiva de particulas no disueltas en un fluido
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
MX347853B (es) Ensayo cuantitativo rapido para medir la funcion del regulador de conductancia de transmembrana de fibrosis quistica (cftr) en un molde de cultivo intestinal primario.
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
MX2016002879A (es) Sistemas, dispositivos y metodos para la terapia anti-tl1a.
WO2015176066A3 (en) Lpa-associated protein and rna expression
EA201690465A1 (ru) Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту
WO2013080050A3 (en) Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
EP2841599A4 (en) METHOD OF IDENTIFYING AGENTS FOR INDUCTING RESPIRATORY SENSITIZATION, AND ARRANGEMENT AND ANALYSIS KITS FOR USE IN THE METHOD
EA201201285A1 (ru) Системы и способы для определения местоположения горизонтальных скважин в пределах заданных границ
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
EA201401201A1 (ru) Способ
PL405125A1 (pl) Cząsteczka miR172 pochodzenia roślinnego lub jej syntetyczny ekwiwalent, sposób zmniejszania proliferacji limfocytów B oraz zastosowanie cząsteczki miR172
GB201016616D0 (en) Method and system for determining characteristics of an embryo and uses thereof
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2011, OBSERVADAS AS CONDICOES LEGAIS.